Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10939618 | 1.00 | CYP1A2 (0.75) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL94068 | 1.00 | CYP1A2 (0.75) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1128098 | 0.98 | CYP1A2 (0.72) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8202520 | 0.98 | CYP1A2 (0.72) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL812920 | 0.97 | CYP1A2 (0.71) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Ethylene SCHEMBL27789472 | 0.95 | CYP1A2 (0.69) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1720619 | 0.95 | CYP1A2 (0.68) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3402164 | 0.92 | — | — | |
| Methylene Chloride SCHEMBL28294345 | 0.91 | CYP1A2 (0.63) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL23886232 | 0.90 | GLA (0.65) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025012376-A1 | IONIZABLE LIPIDS | ETHERNA IMMUNOTHERAPIES NV (BE) | 2025-01-16 | — | — | WO | disclosed |
| US-10640520-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| WO-2016050355-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| WO-2007048918-A1 | NOVEL ESTERIFIED AMINO COMPOUNDS HAVING A HYDROCARBON RING E WITH SIX CAMPTOTHECIN ANALOGUE RING MEMBERS, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048917-A1 | NOVEL ESTERIFIED AMINO COMPOUNDS HAVING A HYDROCARBON RING E WITH SEVEN CAMPTOTHECIN-DERIVED RING MEMBERS, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2007-05-03 | — | — | WO | disclosed |
| EP-1753752-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121133-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-4025630-A | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
| US-3972880-A | TRANQUILIZER | SHARPS ASSOCIATES (US) | 1976-08-03 | — | — | US | disclosed |
| US-3960871-A | ANTIDEPRESSANT, ANALGESICS, ANTICONVULSANT ANTI-ANXIETY ACTIVITY | SHARPS ASSOCIATES (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | CYP1A2 3721/4885MAPK1 1470/4885SMN1; SMN2 2411/4885 |
| US-10640520-B2 | Boronic acid derivatives | BCL9, BCL9L, BCL6 | CYP1A2 3721/4885MAPK1 1470/4885SMN1; SMN2 2411/4885 |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | NAAA, CPS1, COASY | CYP1A2 1660/4885MAPK1 4513/4885SMN1; SMN2 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.